Hanmi Pharm Co Ltd (128940)

Currency in KRW
515,000
+13,000(+2.59%)
Closed·
128940 is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
501,000528,000
52 wk Range
302,000647,000
Key Statistics
Bid/Ask
513,000.00 / 514,000.00
Prev. Close
502,000
Open
507,000
Day's Range
501,000-528,000
52 wk Range
302,000-647,000
Volume
170.49K
Average Volume (3m)
129.73K
1-Year Change
65.0641%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
128940 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
650,833
Upside
+26.38%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Hanmi Pharm Co Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 650,833
(+26.38% Upside)

Earnings

Latest Release
Aug 14, 2026
EPS / Forecast
6,570.00 / 4,062.00
Revenue / Forecast
467.2B / 430.75B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 17,099.95%
Dividend Yield
0.40%
Industry Median 1.10%
Annualized payout
2,000.00
Paid annually
5-Years Growth
-
Growth Streak

128940 Income Statement

Compare 128940 to Peers and Sector

Metrics to compare
128940
Peers
Sector
Relationship
P/E Ratio
30.8x8.7x−0.4x
PEG Ratio
0.300.040.00
Price/Book
4.8x0.8x2.6x
Price / LTM Sales
4.0x0.7x3.0x
Upside (Analyst Target)
24.5%59.3%56.5%
Fair Value Upside
Unlock24.8%8.5%Unlock

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.

Employees
2400

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
993.31K7.83%470.83B
Other Institutional Investors
7.88M62.14%3.74T
Public Companies & Retail Investors
3.81M30.03%1.81T
Total
12.69M100.00%6.01T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Hanmi Science Co., Ltd.41.82%5,306,1212,515,101,354
National Pension Service9.96%1,264,255599,256,870

People Also Watch

48,300
204320
-0.21%
55,900
120110
+3.90%
7,020
073240
-0.14%
41,800
001120
+0.36%
21,100
086450
+1.20%

FAQ

What Is the Hanmi Pharm Co (128940) Stock Price Today?

The Hanmi Pharm Co stock price today is 515,000 KRW.

What Stock Exchange Does Hanmi Pharm Co Trade On?

Hanmi Pharm Co is listed and trades on the Seoul Stock Exchange.

What Is the Stock Symbol for Hanmi Pharm Co?

The stock symbol for Hanmi Pharm Co is "128940."

Does Hanmi Pharm Co Pay Dividends? What’s The Current Dividend Yield?

The Hanmi Pharm Co dividend yield is 0.4%.

What Is the Hanmi Pharm Co Market Cap?

As of today, Hanmi Pharm Co market cap is 6.37T KRW.

What Is Hanmi Pharm Co's Earnings Per Share (TTM)?

The Hanmi Pharm Co EPS (TTM) is 17,100.

When Is the Next Hanmi Pharm Co Earnings Date?

Hanmi Pharm Co will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is 128940 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Hanmi Pharm Co Stock Split?

Hanmi Pharm Co has split 15 times.

How Many Employees Does Hanmi Pharm Co Have?

Hanmi Pharm Co has 2400 employees.

What is the current trading status of Hanmi Pharm Co (128940)?

As of Sep 17, 2026, Hanmi Pharm Co (128940) is trading at a price of 515,000 KRW, with a previous close of 502,000 KRW. The stock has fluctuated within a day range of 501,000 KRW to 528,000 KRW, while its 52-week range spans from 302,000 KRW to 647,000 KRW.

What Is Hanmi Pharm Co (128940) Price Target According to Analysts?

The average 12-month price target for Hanmi Pharm Co is 650,833 KRW, with a high estimate of 760000 KRW and a low estimate of 550000 KRW. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +26.38% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.